Comparative Pharmacology
Head-to-head clinical analysis: DARVON versus NUCYNTA ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON versus NUCYNTA ER.
DARVON vs NUCYNTA ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a mu-opioid receptor agonist that inhibits ascending pain pathways by binding to opioid receptors in the CNS, altering pain perception. It also has weak local anesthetic effects.
Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, providing analgesic effects through opioid receptor activation and modulation of descending pain pathways.
Propoxyphene hydrochloride (Darvon) for moderate to severe pain: 65 mg orally every 4 hours as needed; maximum 390 mg/day.
100 mg orally every 12 hours, titrated from 50 mg every 12 hours; maximum 200 mg every 12 hours.
None Documented
None Documented
6-12 hours (parent drug); norpropoxyphene half-life 30-36 hours, accumulates with repeated dosing, increasing risk of toxicity.
Terminal elimination half-life: 4.1 hours (range 3.3–4.7 h) after single oral dose; steady state: 4.4 h. No clinically relevant accumulation.
Primarily hepatic metabolism to norpropoxyphene, then renal excretion of metabolites; <20% excreted unchanged in urine; minor biliary/fecal elimination.
Renal: 99% (tapentadol and glucuronide conjugates); Fecal: <1%; unchanged tapentadol: <5%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic